Karo Bio AB is finalizing the design of a Phase III program for its lead drug candidate, eprotirome (KB2115), which is in development for heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by the accumulation of elevated levels of low density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis at an early age. (BioWorld International)

PregLem SA is in-licensing an oral, preclinical Jun kinase inhibitor, bentamapimod (AS602801), from Merck Serono SA, for prevention of postsurgical abdominal adhesions and endometriosis in patients. (BioWorld International)

DUBLIN, Ireland – Elan Corp. plc has decided against spinning out its drug delivery arm, Elan Drug Technologies (EDT), into a separate business after concluding that "market conditions at this time are not conducive to an appropriate valuation." (BioWorld International)